Company news
Diasorin S.p.a. (MIL:DIA) news
Diasorin S.p.a. news releases on 6ix. Latest, May 19, 2026: DiaSorin S p A : Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal…
Press releases & updates
DiaSorin S p A : Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay
May 19, 2026
DiaSorin S p A : Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President
May 4, 2026
DiaSorin S p A : Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024
March 20, 2026
DiaSorin S p A : signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform
March 19, 2026
DiaSorin S p A : introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN
February 24, 2026
DiaSorin S p A : submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver
February 3, 2026
DiaSorin S p A : has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL
January 29, 2026
DiaSorin S p A : signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel
January 26, 2026
DiaSorin S p A : Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer.
January 22, 2026
DiaSorin S p A : receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform
December 30, 2025
DiaSorin S p A : receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIASON NES Molecular Diagnostics platform
December 28, 2025
DiaSorin S p A : submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance
November 24, 2025
DiaSorin S p A : , in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark
November 18, 2025
DiaSorin S p A : receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration
October 31, 2025
DiaSorin S p A : signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX
October 22, 2025
DiaSorin S p A : launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark
September 19, 2025
DiaSorin S p A : Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
July 31, 2025
DiaSorin S p A : submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver
July 2, 2025
DiaSorin S p A : announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®
June 7, 2025
DiaSorin S p A : receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX®
April 18, 2025
DiaSorin S p A : Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999
April 3, 2025
DiaSorin S p A : launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark
March 18, 2025